Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Acute AION in Giant Cell Arteritis
NCT04239196Phase 2Unknown
- Sponsor
- Quinze-Vingts Hospital
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in Anterior ischemic optic neuropathy (AION), giant cell arteritis (GCA), sponsored by Quinze-Vingts Hospital. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
Anterior ischemic optic neuropathy (AION)giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT04239196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239196.